ReviewInfectious diseases and therapy2023
Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review.
Review in Infectious diseases and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- The role of natural products in treatment of non-tuberculous mycobacterial infections: a systematic review.Antonie van Leeuwenhoek · 2026Pooled it
- Nontuberculous Mycobacterial Infections at a National Cancer Institute-Designated Comprehensive Cancer Center in Florida.Open forum infectious diseases · 2026Article
- Refractory Mycobacterium fortuitum skin and soft tissue infection following dog bite in a pediatric patient: a case report.BMC pediatrics · 2026Article
- A Case Report on DisseminatedClinical case reports · 2026Article
- Clinical characteristics, antimicrobial susceptibility patterns, and treatment outcomes of nontuberculous mycobacterial diseases in eastern China: a retrospective cohort study (2019-2022).Microbiology spectrum · 2026Article
- Retrospective analysis of non-tuberculous mycobacterial skin infections: diagnostic accuracy, treatment efficacy, and PCR-based species detection in a Chinese primary care hospital.Journal of clinical microbiology · 2025Article
- Analysis of nontuberculous mycobacterial infections in Saudi children from a tertiary care hospital perspective.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Optimising non-pharmacological interventions in people with non-tuberculous mycobacterial pulmonary disease: a systematic review.ERJ open research · 2025Article
- Prevalence and epidemiologic features of nontuberculous mycobacteria causing persistent surgical site infections in Bangladesh.IJID regions · 2025Article
- Early surgical intervention for extensive nontuberculous mycobacterial pulmonary disease.IJTLD open · 2025Article
- Design and Validation of a Simplified Method to Determine Minimum Bactericidal Concentration in Nontuberculous Mycobacteria.Antibiotics (Basel, Switzerland) · 2025Article
- Clinical Characteristics of Nontuberculous Mycobacterial Positivity Occurring During Multidrug-Resistant Tuberculosis Treatment: A Retrospective Study.Tropical medicine and infectious disease · 2025Article
- Bidirectional pathogenesis between non-tuberculous mycobacteria and bronchiectasis: clinical insights, diagnostic challenges and future directions-Perspectives from South Asia.Frontiers in tuberculosis · 2025Review
- Activity of combinations of bactericidal and bacteriostatic compounds inFrontiers in microbiology · 2025Review
- Case Report: First pulmonary infection caused byFrontiers in medicine · 2025Article
- Exploring the Chemical Space of Mycobacterial Oxidative Phosphorylation Inhibitors Using Molecular Modeling.ChemMedChem · 2024Review
- Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers.Antimicrobial agents and chemotherapy · 2024Article
- Sanitary Waters: Is It Worth Looking for Mycobacteria?Microorganisms · 2024Article
- Supporting Patients with Nontuberculous Mycobacterial Pulmonary Disease: Ensuring Best Practice in UK Healthcare Settings.Pharmacy (Basel, Switzerland) · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nontuberculous mycobacteria (NTM) are a group of atypical bacteria that may cause a spectrum of clinical manifestations, including pulmonary, musculoskeletal, skin and soft tissue, and cardiac infections. Antimycobacterial medication regimens for NTM infections require multiple agents with prolonged treatment courses and are often associated with poor tolerance in patients and suboptimal clinical outcomes. This review summarizes NTM pharmacotherapy, including treatment concepts, preferred medication regimens according to NTM species and site of infection, and emerging treatment methods for difficult-to-treat species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.